NASDAQ:SBTX   Silverback Therapeutics, Inc
Silverback Therapeutics Inc (NASDAQ:SBTX) Price has made a new low but reversed it by closing above 9.10 again. There was clearly more buying than selling on Friday. Company has a good pipeline, cash on hand and a great CEO with huge experience (she led Synthorix into its acquisition by Sanofit). According to analysts' consensus price target of $51.80, Silverback Therapeutics has a forecasted upside of 452.2%. I have been accumulating this stock.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.